• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

类风湿关节炎：我们能否使类风湿关节炎患者达到真正的药物缓解？

Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA?

机构信息

Leiden University Medical Center, Department of Rheumatology, C1-R, Albinusdreef 2, Leiden, The Netherlands.

出版信息

Nat Rev Rheumatol. 2010 Feb;6(2):68-70. doi: 10.1038/nrrheum.2009.253.

DOI:10.1038/nrrheum.2009.253
PMID:20125170
Abstract

Since the introduction of new biologic agents and intensive treatment strategies that aim to tightly control disease activity, clinical remission has become a realistic target in patients with rheumatoid arthritis. Once patients are in continuous remission, however, is it realistic to consider withdrawing DMARD therapy?

摘要

自从引入旨在严格控制疾病活动的新型生物制剂和强化治疗策略以来，类风湿关节炎患者的临床缓解已成为现实目标。然而，一旦患者持续缓解，是否可以考虑停用 DMARD 治疗？

相似文献

1
Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA?类风湿关节炎：我们能否使类风湿关节炎患者达到真正的药物缓解？
Nat Rev Rheumatol. 2010 Feb;6(2):68-70. doi: 10.1038/nrrheum.2009.253.
2
Current concepts in the management of rheumatoid arthritis.类风湿关节炎管理的当前概念
Korean J Intern Med. 2016 Mar;31(2):210-8. doi: 10.3904/kjim.2015.137. Epub 2016 Feb 26.
3
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.类风湿关节炎中持续停用改善病情抗风湿药缓解的患病率及预测因素：来自两个大型早期关节炎队列的结果
Arthritis Rheum. 2009 Aug;60(8):2262-71. doi: 10.1002/art.24661.
4
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.在生物制剂可及性有限的地区开展的国际达标治疗研究：依那西普联合 DMARD 治疗与单独 DMARD 治疗在活动性类风湿关节炎中维持缓解的比较。
Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9.
5
Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?类风湿关节炎临床缓解患者的关节损伤进展：生物制剂比合成抗风湿药物效果更好吗？
J Rheumatol. 2014 Aug;41(8):1576-82. doi: 10.3899/jrheum.130767. Epub 2014 Jul 15.
6
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.早期类风湿关节炎中使用单药或联合改善病情抗风湿药物治疗时治疗开始的延迟及缓解的诱导。
Arthritis Rheum. 2002 Apr;46(4):894-8. doi: 10.1002/art.10135.
7
Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.治疗策略是否会影响 RA 患者实现并维持 DMARD 无缓解的能力？一项比较强化 DAS 指导治疗策略与常规治疗中靶向治疗的观察性研究结果。
Arthritis Res Ther. 2019 May 7;21(1):115. doi: 10.1186/s13075-019-1893-z.
8
Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.早期缓解是大多数初治类风湿关节炎患者切实可行的目标。
J Rheumatol. 2016 Apr;43(4):699-706. doi: 10.3899/jrheum.141480. Epub 2016 Feb 15.
9
Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.类风湿关节炎的疾病缓解药物停药后持续缓解：随着疾病症状的消退，越来越有可能实现这一目标。
Ann Rheum Dis. 2016 May;75(5):867-73. doi: 10.1136/annrheumdis-2014-207080. Epub 2015 May 13.
10
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.类风湿关节炎中生物制剂和传统 DMARD 疗法的逐渐减量：当前证据与未来方向。
Ann Rheum Dis. 2016 Aug;75(8):1428-37. doi: 10.1136/annrheumdis-2016-209201. Epub 2016 Jun 3.

引用本文的文献

1
The Differential Expressions and Associations of Intracellular and Extracellular GRP78/Bip with Disease Activity and Progression in Rheumatoid Arthritis.类风湿关节炎中细胞内和细胞外GRP78/Bip的差异表达及其与疾病活动和进展的关联
Bioengineering (Basel). 2025 Jan 13;12(1):58. doi: 10.3390/bioengineering12010058.
2
Barriers to clinical remission in severe asthma.重度哮喘临床缓解的障碍
Respir Res. 2024 Apr 24;25(1):178. doi: 10.1186/s12931-024-02812-3.
3
Machine learning-based prediction of relapse in rheumatoid arthritis patients using data on ultrasound examination and blood test.

本文引用的文献

1
Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.疾病修正抗风湿药物能否在长期类风湿关节炎中停用？一项 15 年随访研究。
Scand J Rheumatol. 2010;39(1):12-8. doi: 10.3109/03009740903042394.
2
Treatment of rheumatoid arthritis: state of the art 2009.类风湿关节炎的治疗：2009年的最新进展
Nat Rev Rheumatol. 2009 Oct;5(10):531-41. doi: 10.1038/nrrheum.2009.182.
3
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
基于机器学习的类风湿关节炎患者超声检查和血液检查数据预测复发。
Sci Rep. 2022 May 4;12(1):7224. doi: 10.1038/s41598-022-11361-y.
4
Asthma remission: what is it and how can it be achieved?哮喘缓解：它是什么，以及如何实现？
Eur Respir J. 2022 Nov 3;60(5). doi: 10.1183/13993003.02583-2021. Print 2022 Nov.
5
Circular RNAs: Promising Biomarkers for Age-related Diseases.环状RNA：与年龄相关疾病的潜在生物标志物
Aging Dis. 2020 Dec 1;11(6):1585-1593. doi: 10.14336/AD.2020.0309. eCollection 2020 Dec.
6
lncRNA expression profiles related to apoptosis and autophagy in peripheral blood mononuclear cells of patients with rheumatoid arthritis.lncRNA 表达谱与类风湿关节炎患者外周血单个核细胞凋亡和自噬的关系。
FEBS Open Bio. 2020 Aug;10(8):1642-1654. doi: 10.1002/2211-5463.12913. Epub 2020 Jul 22.
7
In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics.原位形成可注射水凝胶用于封装奈诺沙星和治疗药物的持续释放。
Int J Nanomedicine. 2019 Nov 6;14:8725-8738. doi: 10.2147/IJN.S214507. eCollection 2019.
8
Circular RNAs Hsa_circ_0002715 and Hsa_circ_0035197 in Peripheral Blood Are Novel Potential Biomarkers for New-Onset Rheumatoid Arthritis.环状 RNAs Hsa_circ_0002715 和 Hsa_circ_0035197 在外周血中是新诊断类风湿关节炎的新型潜在生物标志物。
Dis Markers. 2019 Oct 29;2019:2073139. doi: 10.1155/2019/2073139. eCollection 2019.
9
Identification of circular RNAs hsa_circ_0044235 in peripheral blood as novel biomarkers for rheumatoid arthritis.鉴定外周血中的环状 RNA hsa_circ_0044235 作为类风湿关节炎的新型生物标志物。
Clin Exp Immunol. 2018 Oct;194(1):118-124. doi: 10.1111/cei.13181. Epub 2018 Sep 23.
10
TIPE2 expression is increased in peripheral blood mononuclear cells from patients with rheumatoid arthritis.类风湿关节炎患者外周血单个核细胞中TIPE2表达增加。
Oncotarget. 2017 Sep 23;8(50):87472-87479. doi: 10.18632/oncotarget.21267. eCollection 2017 Oct 20.
类风湿关节炎中持续停用改善病情抗风湿药缓解的患病率及预测因素：来自两个大型早期关节炎队列的结果
Arthritis Rheum. 2009 Aug;60(8):2262-71. doi: 10.1002/art.24661.
4
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.近期发病的类风湿关节炎患者经反应驱动治疗4年后的药物-free缓解、功能状态及影像学损伤情况 。 注：这里“drug-free”直译为“无药物的”，结合语境意译为“未使用药物的”，但为了贴合英文表述习惯，翻译为“药物-free” ，你可根据实际需求调整。
Ann Rheum Dis. 2009 Jun;68(6):914-21. doi: 10.1136/ard.2008.092254. Epub 2008 Jul 28.
5
Optimizing treatment with biologics.优化生物制剂治疗
J Rheumatol Suppl. 2007 Nov;80:16-24.
6
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.类风湿关节炎治疗中的严格控制：疗效与可行性
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii56-60. doi: 10.1136/ard.2007.078360.
7
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).欧洲抗风湿病联盟（EULAR）早期关节炎管理建议：国际临床研究包括治疗学欧洲常务委员会（ESCISIT）特别工作组报告
Ann Rheum Dis. 2007 Jan;66(1):34-45. doi: 10.1136/ard.2005.044354. Epub 2006 Jan 5.
8
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.类风湿关节炎二线药物停药的随机安慰剂对照研究。
Lancet. 1996 Feb 10;347(8998):347-52. doi: 10.1016/s0140-6736(96)90535-8.
9
Preliminary criteria for clinical remission in rheumatoid arthritis.类风湿关节炎临床缓解的初步标准。
Arthritis Rheum. 1981 Oct;24(10):1308-15. doi: 10.1002/art.1780241012.